ArticleInfectious diseases in clinical practice (Baltimore, Md.)2021
Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study.
Article in Infectious diseases in clinical practice (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026Article
- Effect of Early and Delayed Treatment With Remdesivir on Mortality in Patients Hospitalized With COVID-19.Open forum infectious diseases · 2025Article
- Clinical Course and Factors Associated With Hospital Admission and Mortality among Sars-Cov 2 Patients within Nairobi Metropolitan Area.medRxiv : the preprint server for health sciences · 2024Article
- The effect of remdesivir on mortality and the outcome of patients with COVID-19 in intensive care unit: A case-control study.Health science reports · 2023Article
- Article
- Review
- Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia.Microorganisms · 2022Article
- Acute Myocardial Infarction From Embolized Left Ventricular Thrombus in Coronavirus Disease 2019.The journal for nurse practitioners : JNP · 2022Article
- The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.Archives of toxicology · 2022Article
- Co-Administration of Remdesivir and Azithromycin May Protect against Intensive Care Unit Admission in COVID-19 Pneumonia Requiring Hospitalization: A Real-Life Observational Study.Antibiotics (Basel, Switzerland) · 2022Article
- Pharmacological treatment of COVID-19: an opinion paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Early Use of Remdesivir: A Good Start.Infectious diseases in clinical practice (Baltimore, Md.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRemdesivir treatment, like most antiviral drugs, is likely to be most effective when used early in the course of coronavirus disease 2019 (COVID-19). Optimal timing of remdesivir for the treatment of COVID-19 remains unclear.
objectivesThe aim of this study was to determine whether early treatment with remdesivir improves clinical outcomes: length of stay, need for mechanical ventilation, and death.
methodsWe conducted a retrospective observational study of patients hospitalized with COVID-19 who received remdesivir therapy within 10 days of symptom onset at a large health system in Georgia, United States.
resultsWe identified a total of 475 patients. Initiation of therapy 3 days or less from first positive SARS-CoV-2 improved length of stay (15.7 days) compared with those started on therapy more than 3 days after a positive test (19.3 days) (
conclusionsOur data show that early treatment with remdesivir in patients hospitalized with COVID-19 shortened length of stay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.